Newspatrolling.com News cum Content Syndication Portal Online
-
India’s bioeconomy expands from $10B (2014) to $195B (2026), projected to reach ~$300B by 2033
-
Over $300B worth of global drug patents set to expire by 2030, increasing the demand for innovation
-
Globally, R&D costs rise to ~$2.2B per asset; India offers a ‘recruitment alpha’ and the advantage of over 3-4x ‘more shots on goal’ per dollar spent in drug development
-
The recent Biopharma Shakti, PRIP and RDI are strong policy signals and will accelerate biopharma innovation
-
March 2026 New Drugs and Clinical Trials Rules Amendment reduces approval timelines for research, expected to compress development cycles by at least 90–120 days
-
India houses 2,500+ biotech startups, ~100 incubators, 600+ research institutes, and 200+ accredited labs
Bengaluru, March 31, 2026: Endiya Partners today released its latest report, “India’s Biopharma Moment: Perspectives from DEMO Biotech,” highlighting an evolution underway in India’s biopharma landscape from a global leader in generics to a high-velocity, cost-effective hub for global biopharma innovation.
The report underscores that India is at an inflection point, driven by policy tailwinds, regulatory reforms, and the emergence of high quality clinical-stage assets receiving global validation. India’s unique “Recruitment Alpha” and ‘More Shots on Goal’ advantage positions it well to emerge as a global biopharma innovation hub amidst the rising demand for cost-efficient high quality R&D.
Global Realignment Creating Opportunity for India
The global biopharma industry is undergoing a structural reset as R&D costs soar to $2.2 billion per asset and development cycles average 100 months. Driven by a shift toward complex modalities like gene therapies and mRNA, alongside a looming $300 billion patent cliff and geopolitical volatility, the demand for more cost-efficient, high-velocity R&D ecosystems is increasing.
India’s Shift: From ‘Pharmacy of the World’ to ‘Innovation Harbour’
India continues to supply ~20% of global generics and over 60% of vaccines, reinforcing its position as the ‘Pharmacy of the World.’ It is now transitioning toward capability-led innovation in novel biotherapeutics and deep-tech platforms.
Ecosystem Momentum and Key Challenges
India’s bioeconomy has expanded from $10 billion in 2014 to over $195 billion in 2026 (~5% of GDP) and is projected to reach nearly $300 billion by 2033. India’s biopharma ecosystem has scaled significantly, with 2,500+ startups, ~100 incubators, and 600+ research institutes.
Policy Tailwinds: Recent government initiatives, including the ₹10,000 Cr Biopharma Shakti scheme and the ₹1,00,000 Cr RDI Fund, signify a new era of policy maturity, accelerating innovation.
Regulatory Velocity: 2026 reforms, including the 45-day approval timeline and prior intimation pathways, are expected to reduce administrative friction and compress development cycles by at least 90–120 days.
Global Validation Signals a “Valuation Inflection Point”: The report highlights that Indian-origin innovation is reaching a global valuation inflection point, evidenced by major milestones such as the $1.9 billion AbbVie–IGI deal, the US FDA’s acceptance of Wockhardt’s Zaynich NDA, and the advancement of Eyestem’s cell therapy into Phase 2. These developments confirm that Indian biotech IP is now recognized as peer-level to established global clusters, signaling a new era of maturity and impact for the nation’s innovation pipeline.
Indian biotech startups benefit from a ‘Recruitment Alpha’, enrolling patients up to ten times faster and advancing drugs to Phase II with <$50M, enabling 3–4x ‘More Shots on Goal’ compared to the west. However, gaps in pilot scale GMP infrastructure, late-stage funding, talent, and translational research remain.
Outlook: Building a Cost-Efficient High-Velocity Innovation Harbour
Looking ahead, the report outlines four key pillars for growth: Blended Finance for derisking frontier science and enabling exits, building ‘industrial intelligence’, translational infrastructure and a dynamic regulatory architecture.
With sustained policy support and deeper ecosystem collaboration, India is well-positioned to emerge as a global hub for cost-efficient, high-quality biopharma innovation.
What Endiya Sees
“The government has done a good job so far and while definitely policy and government will have to continue to play a role, it is up to investors, incubators, startups, corporates and the rest of the ecosystem to take us further,” said Dr. Ramesh Byrapaneni, Endiya Partners.
“This is a great time to be building biotech in India. With the global industry seeking high-velocity R&D and diversified supply chains, India offers a unique combination of clinical depth, technical talent, and cost-efficiency that allows us to solve the world’s most complex medical challenges at a fraction of the traditional cost,” said Dr. Vedha Sampathkumar, Endiya Partners.
